SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (171)4/5/2018 2:05:30 PM
From: scaram(o)uche1 Recommendation

Recommended By
tuck

  Respond to of 294
 
That's OK, as I've heard that Nic is developing a secret weapon (IgG3 construct) for combination-combination therapies. It's going to be called TTI-623, and is specifically designed to work in combination with PD1/PDL1 and SRF231.

Next in line is the G2 construct, which is meant for aphthous ulcers.



To: tuck who wrote (171)4/5/2018 2:16:18 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 294
 
>> Another competitor that is no longer preclinical <<

Not a problem, heard that Nic is going to take a shot at competitors by rewriting this thread's header.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News